Anticancer Therapies – Multimedia

Complete “Sample-to-Result” Highly Automated NGS and qPCR Workflow for Clinical Diagnostics.

Here we describe a platform of T cell activation bioassays for the development of CD3 bispecific antibodies and engineered T cell immunotherapies.

Professor Peter Johnson - Professor of Medical Oncology, University of Southampton and Chief Clinician for Cancer Research UK.

In this seminar Tom Dubensky talks us through the use of listeria monocytogenes for the development of cancer immunotherapy.

Jeffrey S. Weber, M.D., Ph.D., discusses the cancer immunity cycle and the importance of antigen release and presentation to maximize the potential of immunotherapies.

Download this infographic to discover what makes CD47 an attractive target for the development of novel therapeutics.

In this list, we pay homage to 9 of the most incredible images we’ve seen from the field of cancer research.

Here we describe a live cell imaging based approach to detect GPCR activation using the Lionheart™ FX Automated Live Cell Imager and Gen5™ Microplate Reader and Imager Software.

This article highlights some of the wide range of applications which can be achieved using mass spectrometry.

Professor Awen Gallimore of Cardiff University describes the limitations of current cancer immunotherapy and the role Treg depletion plays.